Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New indication: Olutasidenib for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation - Altai Oncology
  1. Home /
    2. Altai Protocol Library /
  2. New indication: Olutasidenib for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New indication: Olutasidenib for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation

New indication: Olutasidenib for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation
Study:
  • Phase 1/2, multicenter, open-label
  • Treatment-naive and Relapsed or refractory AML; MDS with an IDH1 mutation
  • Olutasidenib monotherapy (n=32) vs. combination with Azacitidine (n=46)
Efficacy:
  • Relapsed or refractory AML: ORR 41% vs. 46%
  • For treatment-naïve AML: ORR 25% vs. 77%
Safety:
  • Grade 3: febrile neutropenia(22% vs. 28%); anemia (22% vs. 20%); pneumonia (16% vs. 9%)

Lancet Haematol. 2023 Jan;10(1): e46-e58.

Watts M J.et al. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

https://doi.org/10.1016/S2352-3026(22)00292-7

Reviewed by Elvin CHALABİYEV, MD on Jan 30, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More